Drag­on­fly gets Mer­ck on sec­ond TriN­KET can­di­date since 2018 col­lab; Chi­nese eye gene ther­a­py de­vel­op­er nabs $60M

Drag­on­fly Ther­a­peu­tics is do­ing bet­ter and bet­ter in get­ting Big Phar­ma on its TriN­KET plat­form. First Cel­gene, then BMS, and now Mer­ck — again.

Af­ter Mer­ck …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.